- The Newly Formed North American Expansion Committee Plans to Accelerate Champignon Brands’ Entry into the Vast United States Market
- Building Off the AltMed Deal Which Saw the Firm Acquire Health Canada Licensed CRTCE Clinic, Champignon Intends to Open/Acquire at Least 5 New Clinics in 2020
- The Psychedelics Leader Continues to Hold Discussions with Revenue-Generating Clinics in New York, California, Florida, Pennsylvania, Texas and Missouri
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced on Monday the formation of a new specialized committee tasked with advancing the company’s North American psychedelics clinic expansion strategy.
Champignon Brands, a leading human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine has ordered its newly formed expansion committee to accelerate the firm’s entry into the U.S. market.
Champignon says it intends to open or acquire at least five new clinics in 2020 with the company disclosing the continuation of ongoing discussions with revenue-generating clinics located in New York, California, Florida, Pennsylvania, Texas and Missouri.
“We will look to capitalize on the fragmented nature of the U.S. ketamine clinic marketplace with the objective of creating a consortium of integrated mood disorder treatment and research facilities,” stated Champignon Brands CEO Gareth Birdsall.
“By leveraging existing protocols, data sets and SOPs from our flagship clinic, the Canadian Rapid Treatment Centre of Excellence, arguably the most advanced integrated mood disorder centre in North America, we will improve economics, increase patient enrollment and function as the pre-eminent brick and mortar staging ground for novel molecule discovery initiatives. Champignon remains bullish on the U.S. marketplace due to favourable co-payer infrastructure, as well as a vast addressable patient population,” added Birdsall.
SHRM Stock Price Action & Chart
Shares of Champignon Brands’ CSE listed ‘SHRM’ stock closed Monday’s trading session at $1.05 per share, up another 7.14% as the surging stock extended its current breakout. South of the border, the company’s U.S. listed ‘SHRMF’ stock jumped 6.99%, closing Monday at $0.75. Overseas in Germany, Champignon’s Frankfurt listed stock outperformed the company’s North American listings, soaring 13.68% to close the session at $0.665 per share.
Champignon Brands is a paid client of The Cannabis Investor. The Cannabis Investor holds a position in Champignon Brands.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.